JP7879130B2 - 変異型株ベースのコロナウイルスワクチン - Google Patents
変異型株ベースのコロナウイルスワクチンInfo
- Publication number
- JP7879130B2 JP7879130B2 JP2023543034A JP2023543034A JP7879130B2 JP 7879130 B2 JP7879130 B2 JP 7879130B2 JP 2023543034 A JP2023543034 A JP 2023543034A JP 2023543034 A JP2023543034 A JP 2023543034A JP 7879130 B2 JP7879130 B2 JP 7879130B2
- Authority
- JP
- Japan
- Prior art keywords
- cov
- sars
- antigen
- mrna
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163138228P | 2021-01-15 | 2021-01-15 | |
| US63/138,228 | 2021-01-15 | ||
| US202163140921P | 2021-01-24 | 2021-01-24 | |
| US63/140,921 | 2021-01-24 | ||
| US202163161439P | 2021-03-15 | 2021-03-15 | |
| US63/161,439 | 2021-03-15 | ||
| US202163173972P | 2021-04-12 | 2021-04-12 | |
| US63/173,972 | 2021-04-12 | ||
| US202163193558P | 2021-05-26 | 2021-05-26 | |
| US63/193,558 | 2021-05-26 | ||
| US202163222930P | 2021-07-16 | 2021-07-16 | |
| US63/222,930 | 2021-07-16 | ||
| US202163241944P | 2021-09-08 | 2021-09-08 | |
| US63/241,944 | 2021-09-08 | ||
| US202163283795P | 2021-11-29 | 2021-11-29 | |
| US63/283,795 | 2021-11-29 | ||
| US202163284565P | 2021-11-30 | 2021-11-30 | |
| US63/284,565 | 2021-11-30 | ||
| PCT/US2022/012607 WO2022155524A1 (en) | 2021-01-15 | 2022-01-14 | Variant strain-based coronavirus vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503698A JP2024503698A (ja) | 2024-01-26 |
| JP2024503698A5 JP2024503698A5 (cg-RX-API-DMAC10.html) | 2025-04-14 |
| JP7879130B2 true JP7879130B2 (ja) | 2026-06-23 |
Family
ID=80222159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543034A Active JP7879130B2 (ja) | 2021-01-15 | 2022-01-14 | 変異型株ベースのコロナウイルスワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240100151A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4277655A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7879130B2 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022208057A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3208486A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022155524A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| DE20164728T1 (de) | 2015-10-22 | 2021-09-30 | Modernatx, Inc. | Impfstoffe gegen atemwegsvirus |
| EP3364949A4 (en) | 2015-10-22 | 2019-07-31 | ModernaTX, Inc. | CANCER VACCINES |
| US12128113B2 (en) | 2016-05-18 | 2024-10-29 | Modernatx, Inc. | Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| EP3668977A4 (en) | 2017-08-18 | 2021-04-21 | Modernatx, Inc. | HPLC ANALYTICAL PROCESSES |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| US12090235B2 (en) | 2018-09-20 | 2024-09-17 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CN113939282A (zh) | 2019-01-31 | 2022-01-14 | 摩登纳特斯有限公司 | 制备脂质纳米颗粒的方法 |
| MX2021010075A (es) | 2019-02-20 | 2021-12-10 | Modernatx Inc | Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales. |
| MX2021011031A (es) | 2019-03-11 | 2021-12-10 | Modernatx Inc | Proceso de transcripción in vitro en lotes alimentados. |
| MA55321A (fr) | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| KR20230011369A (ko) * | 2020-05-18 | 2023-01-20 | 칸시노 (상하이) 바이오테크놀로지스 컴퍼니 리미티드 | mRNA 또는 mRNA 조성물, 및 이의 제조 방법 및 이의 용도 |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| WO2022150717A1 (en) | 2021-01-11 | 2022-07-14 | Modernatx, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| EP4366768A4 (en) * | 2021-07-09 | 2025-05-21 | ModernaTX, Inc. | Pan-human coronavirus vaccines |
| US12397051B2 (en) * | 2021-09-14 | 2025-08-26 | Globe Biotech Limited | Vaccine for use against coronavirus and variants thereof |
| AU2022358982A1 (en) * | 2021-10-06 | 2024-05-23 | Diosynvax Ltd | Coronavirus vaccines |
| WO2023092069A1 (en) * | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| JP2025529906A (ja) * | 2022-08-22 | 2025-09-09 | ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | コロナウイルスに対するワクチン |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2025166202A1 (en) | 2024-01-31 | 2025-08-07 | Modernatx, Inc. | Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof |
| WO2026055709A1 (en) * | 2024-09-09 | 2026-03-12 | Washington University | Mitochondria-facilitated delivery of mrna |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009011A1 (ja) | 2004-07-15 | 2006-01-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | コロナウイルススパイクs1融合蛋白及びその発現ベクター |
| JP2017513956A (ja) | 2014-04-23 | 2017-06-01 | モデルナティーエックス, インコーポレイテッド | 核酸ワクチン |
| JP2018537521A (ja) | 2015-10-22 | 2018-12-20 | モデルナティーエックス, インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| US20200197510A1 (en) | 2015-10-22 | 2020-06-25 | Modernatx, Inc. | Respiratory virus vaccines |
| JP2023511633A (ja) | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスrnaワクチン |
| JP2023513544A (ja) | 2020-02-07 | 2023-03-31 | モデルナティエックス インコーポレイテッド | SARS-COV-2 mRNAドメインワクチン |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE291925T1 (de) | 2001-06-05 | 2005-04-15 | Curevac Gmbh | Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2010531640A (ja) | 2007-06-29 | 2010-09-30 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 毒性化合物の分解方法 |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| SG10201408164XA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| KR20220025112A (ko) | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| EA201492055A1 (ru) | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
| ES2967701T3 (es) | 2013-03-15 | 2024-05-03 | Translate Bio Inc | Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas |
| EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
| SG10201801428RA (en) | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| AU2014375402B2 (en) | 2013-12-30 | 2020-10-01 | CureVac SE | Artificial nucleic acid molecules |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| SG11201901941YA (en) | 2016-09-14 | 2019-04-29 | Modernatx Inc | High purity rna compositions and methods for preparation thereof |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| DE202021004130U1 (de) * | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus-Vakzine |
| EP4139616A1 (en) * | 2020-04-22 | 2023-03-01 | Pfizer Inc. | Coronavirus vaccine |
| AU2021269042A1 (en) * | 2020-05-07 | 2023-02-02 | Translate Bio, Inc. | Optimized nucleotide sequences encoding SARS-CoV-2 antigens |
-
2022
- 2022-01-14 US US18/272,512 patent/US20240100151A1/en active Pending
- 2022-01-14 EP EP22703172.1A patent/EP4277655A1/en active Pending
- 2022-01-14 JP JP2023543034A patent/JP7879130B2/ja active Active
- 2022-01-14 CA CA3208486A patent/CA3208486A1/en active Pending
- 2022-01-14 WO PCT/US2022/012607 patent/WO2022155524A1/en not_active Ceased
- 2022-01-14 AU AU2022208057A patent/AU2022208057A1/en not_active Abandoned
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009011A1 (ja) | 2004-07-15 | 2006-01-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | コロナウイルススパイクs1融合蛋白及びその発現ベクター |
| JP2017513956A (ja) | 2014-04-23 | 2017-06-01 | モデルナティーエックス, インコーポレイテッド | 核酸ワクチン |
| JP2018537521A (ja) | 2015-10-22 | 2018-12-20 | モデルナティーエックス, インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| US20200197510A1 (en) | 2015-10-22 | 2020-06-25 | Modernatx, Inc. | Respiratory virus vaccines |
| JP2023511633A (ja) | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスrnaワクチン |
| JP2023513544A (ja) | 2020-02-07 | 2023-03-31 | モデルナティエックス インコーポレイテッド | SARS-COV-2 mRNAドメインワクチン |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3208486A1 (en) | 2022-07-21 |
| JP2024503698A (ja) | 2024-01-26 |
| US20240100151A1 (en) | 2024-03-28 |
| AU2022208057A1 (en) | 2023-08-03 |
| EP4277655A1 (en) | 2023-11-22 |
| WO2022155524A1 (en) | 2022-07-21 |
| AU2022208057A9 (en) | 2024-05-09 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250114 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250404 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251016 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260119 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260512 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260611 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7879130 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |